Treating autoimmune disease

1. A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (II):

or pharmaceutically acceptable salt thereof;

wherein:

R 1 is halo;

X is —(C═O)NR 4 —,

Y is

 and

R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl.

2. The method of claim 1 , wherein said mammal is a human.

3. The method of claim 1 , wherein said autoimmune disease is selected from the group consisting of lupus, rheumatoid arthritis, spondyloarthropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, and multiple sclerosis.

4. The method of claim 1 , wherein said autoimmune disease is systemic lupus erythematosus, cutaneous lupus, drug-induced lupus, or neonatal lupus.

5. A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (IIa):

or a pharmaceutically acceptable salt thereof;

wherein:

R 1 is halo;

X is —(C═O)NR 4 —;

Y is

 and

R2, R3, and R4 are each independently H or an unsubstituted alkyl.

6. The method of claim 1 , wherein said SCD1 polypeptide inhibitor is 2-{[4-(2-chlorophenoxy)piperidine-1-carbonyl]amino}-N-methylpyridine-4-carboxamide:

or a pharmaceutically acceptable salt thereof.

7. A method for treating a mammal having an autoimmune disease, wherein said method comprises administering a SCD1 polypeptide inhibitor to said mammal, wherein said SCD1 polypeptide inhibitor is a compound having Formula (I):

or a pharmaceutically acceptable salt thereof;

wherein:

R 1 is an unsubstituted C 1-6 alkyl or C 1-6 haloalkyl;

X is

Y is selected from:

m is 0 or 1;

n is 0, 1, or 2;

V is NR 4 or O;

R 2 , R 3 , and R 4 are each independently H or an unsubstituted C 1-6 alkyl; and

Z is an unsubstituted aryl.

8. The method of claim 7 , wherein said SCD1 polypeptide inhibitor is a compound having Formula (Ia):

or a pharmaceutically acceptable salt thereof.

9. The method of claim 7 , wherein said SCD1 polypeptide inhibitor is 2-(benzyloxy)-5-{[hydroxy({4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl})methyl]amino}-1,2-dihydropyridin-2-ylium-1-ide:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 1 , said method further comprising identifying the mammal as having said autoimmune disease.

11. The method of claim 5 , wherein said method further comprises identifying the mammal as having said autoimmune disease.

12. The method of claim 5 , wherein said mammal is a human.

13. The method of claim 5 , wherein said autoimmune disease is selected from the group consisting of lupus, rheumatoid arthritis, spondyloarthropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, and multiple sclerosis.

14. The method of claim 5 , wherein said autoimmune disease is systemic lupus erythematosus, cutaneous lupus, drug-induced lupus, or neonatal lupus.

15. The method of claim 7 , wherein said method further comprises identifying the mammal as having said autoimmune disease.

16. The method of claim 7 , wherein said mammal is a human.

17. The method of claim 7 , wherein said autoimmune disease is selected from the group consisting of lupus, rheumatoid arthritis, spondyloarthropathy, Sjogren's syndrome, polymyositis, dermatomyositis, scleroderma, and multiple sclerosis.

18. The method of claim 7 , wherein said autoimmune disease is systemic lupus erythematosus, cutaneous lupus, drug-induced lupus, or neonatal lupus.